Nctid:
NCT06223581
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D001249", "term"=>"Asthma"}], "ancestors"=>[{"id"=>"D001982", "term"=>"Bronchial Diseases"}, {"id"=>"D012140", "term"=>"Respiratory Tract Diseases"}, {"id"=>"D008173", "term"=>"Lung Diseases, Obstructive"}, {"id"=>"D008171", "term"=>"Lung Diseases"}, {"id"=>"D012130", "term"=>"Respiratory Hypersensitivity"}, {"id"=>"D006969", "term"=>"Hypersensitivity, Immediate"}, {"id"=>"D006967", "term"=>"Hypersensitivity"}, {"id"=>"D007154", "term"=>"Immune System Diseases"}], "browseLeaves"=>[{"id"=>"M4556", "name"=>"Asthma", "asFound"=>"Bronchial Asthma", "relevance"=>"HIGH"}, {"id"=>"M5258", "name"=>"Bronchial Diseases", "relevance"=>"LOW"}, {"id"=>"M14977", "name"=>"Respiratory Tract Diseases", "relevance"=>"LOW"}, {"id"=>"M11168", "name"=>"Lung Diseases", "relevance"=>"LOW"}, {"id"=>"M11170", "name"=>"Lung Diseases, Obstructive", "relevance"=>"LOW"}, {"id"=>"M10018", "name"=>"Hypersensitivity", "relevance"=>"LOW"}, {"id"=>"M14967", "name"=>"Respiratory Hypersensitivity", "relevance"=>"LOW"}, {"id"=>"M10020", "name"=>"Hypersensitivity, Immediate", "relevance"=>"LOW"}, {"id"=>"M10200", "name"=>"Immune System Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Respiratory Tract (Lung and Bronchial) Diseases", "abbrev"=>"BC08"}, {"name"=>"Immune System Diseases", "abbrev"=>"BC20"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"studyType"=>"OBSERVATIONAL", "designInfo"=>{"timePerspective"=>"CROSS_SECTIONAL", "observationalModel"=>"COHORT"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>30}, "patientRegistry"=>false}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-01-17", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-01", "completionDateStruct"=>{"date"=>"2026-04-01", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-01-16", "studyFirstSubmitDate"=>"2023-11-22", "studyFirstSubmitQcDate"=>"2024-01-16", "lastUpdatePostDateStruct"=>{"date"=>"2024-01-25", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-01-25", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2026-01-01", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"To Evaluation of cardiac burden in patients with sever bronchial asthma", "timeFrame"=>"Baseline", "description"=>"For Early detection and avoidance of cardiac effects in severe asthma patients"}]}, "oversightModule"=>{"isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"conditions"=>["Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma"]}, "descriptionModule"=>{"briefSummary"=>"Evaluation of cardiac burden in patients with sever bronchial asthma", "detailedDescription"=>"Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades (1).\n\n1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.\n2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT"], "maximumAge"=>"50 years", "minimumAge"=>"18 years", "samplingMethod"=>"NON_PROBABILITY_SAMPLE", "studyPopulation"=>"Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades .\n\n1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.\n2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia.3-3-Heart diseases are the most common cause of", "eligibilityCriteria"=>"Inclusion Criteria:\n\n* Patients accepted to be involved in the study.\n* Patients \\>18 years old .\n\nExclusion Criteria:\n\n* severe bronchial asthma patients who have other comorbidities as (chronic chest disease as COPD,ILD, bronchiectasis , , diabetic ,hypertensive ,mechanical ventilated patients, tracheostomized patients, ......)\n* patients \\<18 years old . patients refuse to be involved in the study ."}, "identificationModule"=>{"nctId"=>"NCT06223581", "briefTitle"=>"Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma", "organization"=>{"class"=>"OTHER", "fullName"=>"Assiut University"}, "officialTitle"=>"Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma", "orgStudyIdInfo"=>{"id"=>"Cardiac burden in sever asthma"}}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"ECHO in sever asthma patient", "type"=>"OTHER", "description"=>"Evaluation of cardiac burden in patients with sever bronchial asthma"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Assiut University", "class"=>"OTHER"}, "responsibleParty"=>{"type"=>"PRINCIPAL_INVESTIGATOR", "investigatorTitle"=>"Principal investigator", "investigatorFullName"=>"Ahmad Hany Anwer Ahmed", "investigatorAffiliation"=>"Assiut University"}}}}
